Abstract 15687: Reasons for Statin Discontinuation With and Without a Physician’s Advice: Data From the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study
Introduction: It is unknown how often adults discontinue statin therapy under the advice of their physician. The reasons for discontinuation may differ among those who stop therapy with versus without their physician’s advice.
Methods: Among 4,989 participants in the population-based REGARDS study who reported ever taking a statin, we determined the percentage who discontinued therapy with their physician’s advice overall and by reason for statin discontinuation. Possible reasons for statin discontinuation were side effects, perceived lack of need, and cost. Participants could report multiple or none of these reasons.
Results: Overall, 1,410 (28.3%) participants discontinued statins. Of these, 53.2% reported side effects as a reason for statin discontinuation, while 22.9% did not think they needed a statin and 3.2% discontinued therapy due to cost. Overall, 48.1% of participants discontinued statin therapy with their physician’s advice. Compared to participants who discontinued statins without their physician’s advice, those who discontinued with their physician’s advice were more likely to report discontinuing therapy due to side effects and less likely to report perceived lack of need or cost as a reason for discontinuation (Table). After multivariable adjustment, discontinuing statin therapy with a physician’s advice was more common for participants who discontinued due to side effects [adjusted prevalence ratio (PR): 1.86 (95% CI: 1.62 - 2.13)], and less common for participants who discontinued therapy due to perceived lack of need or cost [adjusted PR: 0.64 (95% CI: 0.53 - 0.77) and 0.55 (95% CI: 0.32 - 0.94), respectively].
Conclusions: Most participants who discontinued statin therapy due to side effects did so with their physician’s advice, whereas most of those who discontinued due to perceived lack of need or cost did so without their physician’s advice, suggesting a need for physicians to query about these barriers to maintaining statin therapy.
Author Disclosures: R.M. Tanner: None. M.M. Safford: Research Grant; Modest; Amgen Inc. K.L. Monda: Employment; Significant; Amgen, Inc. B. Taylor: Employment; Significant; Amgen, Inc. L.D. Colantonio: None. R. Dent: Employment; Significant; Amgen, Inc. M.E. Farkouh: Research Grant; Significant; Amgen, Inc. P. Muntner: Research Grant; Significant; Amgen. Consultant/Advisory Board; Modest; Amgen. R.S. Rosenson: Research Grant; Significant; Amgen, AstraZeneca, Catabasis, Medicines Company, Sanofi. Honoraria; Modest; Kowa. Consultant/Advisory Board; Modest; Amgen, Akcea, AstraZeneca, CVS Caremark, Eli Lilly, GSK, Sanofi.
- © 2016 by American Heart Association, Inc.